StockData
GRCENasdaqPharmaceutical PreparationsFiscal year ends March 31

Grace Therapeutics, Inc.

Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.88−0.01 (-0.53%)

Close on Oct 19, 2026

Market cap
$32.47M
P/E (TTM)
–
Dividend yield
–

Grace Therapeutics, Inc. revenue by segment

AnnualQuarterlyTTM

No segment breakdown reported

Grace Therapeutics does not break out revenue by segment, region or product in the tagged data of its filings for this period type.